Hemab Therapeutics Holdings, Inc. (COAG) Key Metrics
COAG valuation today
Trailing 12 months · as of October 18, 2026- Market cap
- $1.40B
- Enterprise value
- $1.26B
- P/E (TTM)
- —
- Forward P/E
- —
- PEG ratio
- —
- Price / sales
- —
- Price / book
- 3.8
- EV / EBITDA
- —
- Dividend yield
- —
- Beta
- —
COAG key metrics, 2024–2025
Fiscal year ended December 31, 2025 · U.S. dollarsCOAG returns How much profit the business earns on the capital it uses.
COAG per-share figures Results divided by the shares outstanding at year-end.
COAG financial health Debt, liquidity and how easily interest is covered.
COAG returns on capital
Net income (ROE, ROA) or after-tax operating income (ROIC) divided by the average of the opening and closing balance.
COAG debt vs cash
Debt includes short- and long-term borrowings and, where reported, lease liabilities.
COAG key metrics
2024–2025| 2025 | 2024 | |
|---|---|---|
| Per share | ||
| Revenue per share | $0.00 | $0.00 |
| Earnings per share | −$2.33 | −$1.10 |
| Operating cash flow per share | −$2.24 | −$1.03 |
| Free cash flow per share | −$2.24 | −$1.04 |
| Cash per share | $6.76 | $1.68 |
| Book value per share | −$6.44 | −$2.61 |
| Tangible book value per share | −$6.44 | −$2.61 |
| Capex per share | $0.00 | $0.01 |
| Debt per share | $0.04 | — |
| Shares outstanding | 27.4M | 44.2M |
| Change in shares outstanding | −37.9% | — |
| Returns & profitability | ||
| Return on assets (ROA) | −43.9% | −50.6% |
| Return on tangible assets | −32.8% | −50.6% |
| Financial health | ||
| Total debt | $1.2M | — |
| Cash & short-term investments | $185.5M | $74.4M |
| Net debt | −$184.3M | −$74.4M |
| Debt / assets | 0.01 | — |
| Current ratio | 18.03 | 13.95 |
| Quick ratio | 18.03 | 13.95 |
| Working capital | $181.9M | $86.5M |
| Invested capital | −$360.9M | −$189.7M |
| Tangible asset value | −$176.6M | −$115.3M |
| Net current asset value | −$178.9M | −$118.3M |
| Graham net-net per share | −$6.70 | −$3.10 |
| Capital allocation | ||
| Capex / depreciation | 0.05 | 1.14 |
| Efficiency | ||
| Receivables turnover | 0.00 | — |
| Asset turnover | 0.00 | 0.00 |
| Average receivables | $2.6M | — |
| Average payables | $4.4M | $3.2M |
| Intangibles / total assets | 0.0% | 0.0% |
Computed from COAG's annual financial statements (latest annual report filed December 31, 2025) and the closing share price on each fiscal year-end, adjusted for stock splits. Figures in U.S. dollars; data from EODHD. Averages use the opening and closing balance of each year.
COAG valuation and financial ratios
It ended the year with $1.2 million of debt and $185.5 million in cash and short-term investments, a net cash position of $184.3 million.
See the COAG income statement, the COAG chart for price history, or the COAG stock overview for the latest quote and news.
COAG key metrics FAQ
How much debt does Hemab Therapeutics have?
Hemab Therapeutics had total debt of $1.2 million at the end of fiscal 2025 and more cash than debt.
What is Hemab Therapeutics's current ratio?
Hemab Therapeutics's current ratio was 18.03 at the end of fiscal 2025: current assets were 18.03 times current liabilities.